Literature DB >> 27866682

[Adolescent and Young Adults (AYAS) brain tumor national Web conference. On behalf of ANOCEF, GO-AJA and SFCE societies].

Didier Frappaz1, Marie-Pierre Sunyach2, Emilie Le Rhun3, Marie Blonski4, Valérie Laurence5, Alice Bonneville Levard2, Hugues Loiseau6, David Meyronnet7, Arnaud Callies8, F Laigle-Donadey9, Cecile Faure Conter10.   

Abstract

The skills of adult versus pediatric neuro-oncologists are not completely similar though additive. Because the tumors and their protocols are different and the tolerance and expected sequelae are specific. Multidisciplinary meetings including adult and pediatric neuro-oncologists are warranted to share expertise. Since 2008, a weekly national web based conference was held in France. Any patient with the following criteria could be discussed: Adolescent and Young Adults aged between 15 and 25 years, and any adult with a pediatric type pathology, including medulloblastoma, germ cell tumors, embryonic tumors, ependymoma, pilocytic astrocytoma.
RESULTS: Attendance during the year 2015 was as follows: 42 meetings were held; the median number of cases discussed at each meeting was 4 (1 to 8); the mean number of attendants was 7 (2 to 12). One hundred and sixty-eight cases concerning 121 patients were discussed. Mean age was 30 years old (7 to 67). Forty-eight percent were discussed at diagnosis. The patients had mostly medulloblastomas (40%), germ cell tumors (11%), ependymomas (11%), pineal tumors (7%) and embryonal tumors (8%). The rate of inclusion in protocols was increased since the opening of this web conference, especially for the germ cell tumor SIOP protocol that is opened without age restriction, and in RSMA standard risk or MEVITEM relapse adult medulloblastoma protocols.
CONCLUSION: Multidisciplinary Web conference for AYAs is feasible and increases the inclusion rate in protocols. It should be developed further.
Copyright © 2016 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Adolescents; Brain tumors; Germ cell tumors; Jeunes adultes; Medulloblastoma; Multidisciplinarity; Multidisciplinarité; Médulloblastome; Tumeurs cérébrales; Tumeurs germinales malignes; Young adults

Mesh:

Year:  2016        PMID: 27866682     DOI: 10.1016/j.bulcan.2016.10.010

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  4 in total

1.  An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008-2013.

Authors:  Sam Ng; Sonia Zouaoui; Faiza Bessaoud; Valérie Rigau; Alexandre Roux; Amélie Darlix; Fabienne Bauchet; Hélène Mathieu-Daudé; Brigitte Trétarre; Dominique Figarella-Branger; Johan Pallud; Didier Frappaz; Thomas Roujeau; Luc Bauchet
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

2.  MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.

Authors:  Didier Frappaz; Marc Barritault; Laure Montané; Florence Laigle-Donadey; Olivier Chinot; Emilie Le Rhun; Alice Bonneville-Levard; Andreas F Hottinger; David Meyronnet; Anne-Sophie Bidaux; Gwenaële Garin; David Pérol
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 13.029

Review 3.  Benefits and drawbacks of videoconferencing for collaborating multidisciplinary teams in regional oncology networks: a scoping review.

Authors:  Lidia S van Huizen; Pieter U Dijkstra; Sjoukje van der Werf; Kees Ahaus; Jan Ln Roodenburg
Journal:  BMJ Open       Date:  2021-12-09       Impact factor: 2.692

4.  Central nervous system germ cell tumor, an archetypal AYA tumor and a model for pediatric and neuro-oncology collaboration, review from the EURACAN domain 10 group.

Authors:  Cecile Faure Conter; Gabriele Calaminus; James Nicholson; Ahmed Idbaih; Khê Hoang Xuan; Alexandre Vasiljevic; Giovanni Morana; Alexandru Szathmari; Thankamma Ajithkumar; Didier Frappaz
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.